Researchers at Prosetta Antiviral have used an in vitro screen to identify small molecules targeting the host-catalyzed capsid assembly pathway for the rabies virus. The biotech has partnered with Bristol-Myers to use the screen to identify small molecules targeting the pathway for HIV.